Research
Hormonal
Tirzepatide has a favorable safety profile but requires further investigation.
Practitioners should consider tirzepatide as a treatment option while monitoring for adverse reactions.
StrongSupportsmedium confidence
Tirzepatide has a favorable safety profile but requires further investigation.
Why this rating
Based on clinical trial data mentioned in the abstract.
Source
Safety analysis of tirzepatide in clinical practice
К. О. Shnaider et al. · Glavvrač (Chief Medical Officer) · 2025
DOI 10.33920/med-03-2508-03
other
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →